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Background: Congenital thrombotic thrombocytopenic purpura (TTP), also known as Upshaw-Schulman Syndrome
is a rare inherited deficiency of ADAMTS13. Unlike the more common acquired TTP which is characterized by an
acquired inhibitor of ADAMTS13, patients with congenital TTP have an absolute deficiency of ADAMTS13 without
an inhibitor. Congenital TTP generally presents in infancy with repeat episodes of acute hemolysis and evidence of
microangiopathy, these episodes are usually triggered by illness or physiological stress. Congenital TTP can be effectively
treated with plasma infusion either during acute episodes or on a prophylactic schedule to prevent episodes.
Case presentation: We present a case of a 25 year old Caucasian woman with no know family history of hematological
disorders with congenital TTP. She presented with episodes of hemolysis since infancy, but without clear evidence
of microangiopathy until the age of 25. At presentation to our center the patient was documented to have
thrombocytopenia, elevated creatinine, and schistocytes. She was initially treated with plasma infusion at a rate of
60 ml/hr continuously for a 24 hr period with resolution of her thrombocytopenia and hemolysis. At the time of
writing this article she is maintained on a prophylactic schedule of biweekly plasma infusions at 10 mg/kg and is
maintaining a normal platelet count with no evidence of hemolysis.
Conclusion: Congenital TTP is a rare condition, and the above case is atypical as the patient did not present with
clear evidence of microangiopathy until adulthood. Although this a rare condition it is important for physicians to
be aware of as it, especially the possibility of atypical presentations, as the condition is potentially fatal and
effective treatment exists.
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Congenital thrombotic thrombocytopenic purpura (TTP),
also known as Upshaw-Schulman Syndrome, is a rare
inherited deficiency of A Disintegrin and Metalloprotein-
ase with Thrombospondin Motifs 13 (ADAMTS13). In
1960 Schulman et al. described a case of an 8-year-old girl
who experienced repeated episodes of thrombocytopenia
that improved with plasma infusions. Schulman postulated
that a factor in normal plasma that promoted platelet
production or maturation was absent in his patient [1].
In 1978 Upshaw described a similar case of a 29-year-old
with recurrent episodes of thrombocytopenia associated
with microangiopathic hemolytic anemia (MAHA) that* Correspondence: Andrea.Kew@cdha.nshealth.ca
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unless otherwise stated.also responded to plasma infusions. Upshaw documented
32 episodes of MAHA in his patient over an 11-year
period, the majority of which were preceded by infections
or other stressors, such as pregnancy and surgery [2].
In 1982 Moake et al. identified unusually large von
Willebrand Factor (vWF) multimers in the plasma of
four patients with chronic relapsing TTP. He postulated
that these patients lacked a plasma factor necessary for
cleaving large vWF multimers [3]. It has subsequently
been demonstrated that ADAMTS13 is the vWF-cleaving
protease that is deficient in congenital TTP [4,5]. Lotta
et al. found that residual plasma ADAMST13 activity
levels in patients with congenital TTP correlated with dis-
ease severity, as lower activity was associated with earlier
onset of symptoms, requirement of plasma infusions at an
earlier age, increased annual rates of episodes of TTP, and
need for prophylactic plasma infusions [6]. The natural
history of congenital TTP is one of relapsing episodes ofl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Peripheral blood film showing schistocytes and marked
decrease in platelet number indicating microangiopathic
hemolytic anemia.
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described the majority of patients, 23 out of 43 receiving
an appropriate diagnosis before the age of 15. The usual
presentation for the subjects in this study presenting in
childhood was neonatal jaundice [7]. These episodes
can occur spontaneously but are often triggered by
physiological stressors [8]. The underlying ADAMTS13
deficiency in congenital TTP can be addressed by treat-
ment with fresh frozen plasma (FFP), which contains
physiological amounts of the ADAMTS13 enzyme, thus
prophylactic administration of FFP can be an effective
patient management strategy for this condition. To this
end, Barbot et al. describe a case of a 14-year-old girl with
intractable TTP that initially improved with FFP treat-
ment, but consistently relapsed. She was therefore given
prophylactic FFP infusions at a dose of 10 mg/kg once
every three weeks, which prevented further TTP relapse
during the 10 years of follow-up reported in this case [9].
Case presentation
We present a case of a 25 year old Caucasian woman
with no know family history of hematological disorders
with a history of thrombocytopenia since childhood who
was ultimately diagnosed with and treated for congenital
TTP at the age of 25. She presented at the age of 22 with
a platelet count of 20 × 109/L, an elevated lactate dehydro-
genase (LDH) level of 473 U/L (normal range: 98-192 U/L),
and an indirect bilirubin of 57.0 umol/L (normal range:
0.0-12.0 umol/L). She was completely asymptomatic,
though she described a history of recurrent episodic
easy bruising, jaundice, diarrhea, and fevers since infancy.
As a child she also experienced episodes of epistaxis, gin-
gival bleeding, and hematuria. She is Caucasian with no
personal or family history of hematological disorders or
consanguinity, and no family members known to share
her clinical presentation. She was initially diagnosed with
chronic immune thrombocytopenic purpura (ITP) and
Evans syndrome as a child, and received various treat-
ment regimens including IVIG as well as numerous
courses of prednisone and cyclosporine, none of which
significantly improved her condition. Treatment options
were discussed and since she was asymptomatic and her
platelet levels were felt to be safe the patient elected to
proceed with expectant therapy and regular follow-up,
which was relatively uneventful for several years. At the
age of 25 she presented to another medical institution
with fever, chills, vomiting, and dark urine. Blood work
was significant for elevated creatinine, a platelet count of
10 × 109/L, hemoglobin of 94 g/L and schistocytes in the
peripheral smear. She was admitted to hospital with a
diagnosis of TTP. Her attending physician ordered
ADAMTS13 testing on the suspicion of congenital TTP.
The ADAMTS13 functional assay showed an activity level
of less than 10% and there was no evidence of anti-ADAMTS13 antibodies, establishing the diagnosis of
congenital TTP. She ultimately recovered without under-
going plasma infusions and was discharged home. Regular
screening blood work continued to show evidence of mild
hemolysis. Five months after discharge the patient’s blood
work showed schistocytes in the peripheral smear and a
platelet count of 20 × 109 (Figure 1). Her blood work was
also significant for indirect bilirubin of 42.9 umol/L, and a
LDH level of 491 U/L. She was admitted to our inpatient
service and treated with a plasma infusion at 60 ml/h con-
tinuously for a 24 hour period, which resulted in a marked
improvement in her thrombocytopenia and hemolysis.
One month after being discharged from hospital she again
developed marked thrombocytopenia with a platelet count
of 19 × 109/L and laboratory indications of hemolysis. She
was admitted to hospital, treated successfully, and dis-
charged home with a plan to start prophylactic plasma
infusions at a dose of 10 mg/kg every three weeks. Unfor-
tunately, three weeks later and just prior to receiving her
first prophylactic plasma infusion, she relapsed and was
again admitted for treatment.
Given her recurrent episodes of TTP, the patient was
scheduled to receive weekly prophylactic plasma infu-
sions at a dose of 10 mg/kg. This regimen was followed
for five weeks before the treatment interval was in-
creased. At the time of preparation of this manuscript
our patient is maintained on biweekly plasma infusions;
she has not developed any further episodes of acute
hemolysis and her platelet count remains normal.
Conclusion
Congenital TTP is a rare disorder caused by inherited
ADAMTS13 deficiency, presenting as recurrent episodes
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clinicopathological perspective since, despite a long
history of thrombocytopenia and hemolysis; however
during these earlier episodes there was no evidence of
end organ damage. She did not present with clear evi-
dence of microangiopathy with schistocytes and elevated
creatinine until the age of 25. Though rare, congenital
TTP should be included in any differential diagnosis that
includes acquired TTP, especially in the context of intract-
able TTP. Our case illustrates the importance of a proper
diagnosis of this condition, which warrants long term
follow-up and may require prophylactic FFP infusions.
The decision to initiate prophylactic plasma infusions for
patients with congenital TTP depends on the severity and
frequency of episodes of TTP. Prior to receiving a defini-
tive diagnosis of congenital TTP, our patient had not expe-
rienced any episodes of TTP for several years; however,
between remote episodes of TTP her laboratory parame-
ters showed evidence of mild hemolysis and low platelet
counts. This baseline hemolysis and thrombocytopenia,
coupled with three consecutive relapsing episodes of TTP
post-therapeutic FFP infusions, guided our decision to
continue with regular prophylactic FFP. This decision was
not made lightly, due to the inherent risks associated with
administration of any blood product. To this end we keenly
await the availability of the recombinant ADAMTS13
enzyme product for a potentially safer alternative to FFP
for treatment of congenital TTP.Consent
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